Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.

Fotios LoupakisGiulia MaddalenaIlaria DepetrisSabina MurgioniFrancesca BergamoAngelo Paolo Dei TosMassimo RuggeGiada MunariAndrew NguyenChristopher SzetoVittorina ZagonelSara LonardiMatteo Fassan

Published in: Journal for immunotherapy of cancer (2019)

The present case supports the efficacy of immune checkpoint inhibition in mCRC with heterogeneity in MMR/microsatellite instability status. Clinical issues that may arise in these rare patients are discussed in detail.

Keyphrases

metastatic colorectal cancer
end stage renal disease
single cell
ejection fraction
newly diagnosed
chronic kidney disease
dna damage
cell cycle
oxidative stress
replacement therapy